TargeGen Acquired By Sanofi-aventis
socalTECH
JUNE 30, 2010
TargeGen's products are also potentially useful in treating certain forms of leukemia, lymphoma, other hematological malignancies and blood disorders. Tags: targegen sanofi aventis merger acquisition lifescience bioscience. According to TargeGen, the deal's purchase price depends on the achievement of certain future milestones events.
Let's personalize your content